ATE374255T1 - Doping bei der walk-through-mutagenese - Google Patents
Doping bei der walk-through-mutageneseInfo
- Publication number
- ATE374255T1 ATE374255T1 AT03726328T AT03726328T ATE374255T1 AT E374255 T1 ATE374255 T1 AT E374255T1 AT 03726328 T AT03726328 T AT 03726328T AT 03726328 T AT03726328 T AT 03726328T AT E374255 T1 ATE374255 T1 AT E374255T1
- Authority
- AT
- Austria
- Prior art keywords
- prototype
- predetermined
- synthesis
- polypeptide
- amino acid
- Prior art date
Links
- 238000002703 mutagenesis Methods 0.000 title abstract 2
- 231100000350 mutagenesis Toxicity 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000003786 synthesis reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37368602P | 2002-04-17 | 2002-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374255T1 true ATE374255T1 (de) | 2007-10-15 |
Family
ID=29251060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726328T ATE374255T1 (de) | 2002-04-17 | 2003-04-16 | Doping bei der walk-through-mutagenese |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040033569A1 (de) |
| EP (1) | EP1495142B1 (de) |
| JP (1) | JP4433798B2 (de) |
| CN (1) | CN1653193A (de) |
| AT (1) | ATE374255T1 (de) |
| AU (1) | AU2003228568A1 (de) |
| CA (1) | CA2482769C (de) |
| DE (1) | DE60316547T2 (de) |
| ES (1) | ES2295584T3 (de) |
| MX (1) | MXPA04010222A (de) |
| NZ (1) | NZ535928A (de) |
| WO (1) | WO2003089671A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE528396T1 (de) | 2004-07-06 | 2011-10-15 | Bioren Inc | Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften |
| EP1781680B8 (de) | 2004-07-06 | 2016-05-18 | Bioren, LLC | Universelle antikörperbibliotheken |
| WO2006014477A1 (en) * | 2004-07-06 | 2006-02-09 | Bioren, Inc. | HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5215889A (en) * | 1988-11-18 | 1993-06-01 | The Regents Of The University Of California | Catalytic and reactive polypeptides and methods for their preparation and use |
| CA2079802C (en) * | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
| EP0728015B1 (de) * | 1992-06-18 | 2006-03-08 | Creagen, Inc. | Verfahren zur herstellung eines sets von kombinatorischen polypeptidantigenen |
| AU1874997A (en) * | 1996-02-15 | 1997-09-02 | Pangenetics B.V. | Molecules for the induction of immunological tolerance |
| DE60035434T2 (de) * | 1999-12-27 | 2008-05-15 | Crucell Holland B.V. | Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken |
-
2003
- 2003-04-16 WO PCT/US2003/011935 patent/WO2003089671A1/en not_active Ceased
- 2003-04-16 JP JP2003586379A patent/JP4433798B2/ja not_active Expired - Fee Related
- 2003-04-16 NZ NZ535928A patent/NZ535928A/en unknown
- 2003-04-16 CN CN03811148.9A patent/CN1653193A/zh active Pending
- 2003-04-16 AU AU2003228568A patent/AU2003228568A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010222A patent/MXPA04010222A/es unknown
- 2003-04-16 US US10/417,895 patent/US20040033569A1/en not_active Abandoned
- 2003-04-16 CA CA2482769A patent/CA2482769C/en not_active Expired - Fee Related
- 2003-04-16 ES ES03726328T patent/ES2295584T3/es not_active Expired - Lifetime
- 2003-04-16 AT AT03726328T patent/ATE374255T1/de not_active IP Right Cessation
- 2003-04-16 EP EP03726328A patent/EP1495142B1/de not_active Expired - Lifetime
- 2003-04-16 DE DE60316547T patent/DE60316547T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04010222A (es) | 2005-03-07 |
| ES2295584T3 (es) | 2008-04-16 |
| JP4433798B2 (ja) | 2010-03-17 |
| US20040033569A1 (en) | 2004-02-19 |
| DE60316547D1 (de) | 2007-11-08 |
| NZ535928A (en) | 2006-09-29 |
| EP1495142B1 (de) | 2007-09-26 |
| WO2003089671A1 (en) | 2003-10-30 |
| JP2005523026A (ja) | 2005-08-04 |
| CA2482769A1 (en) | 2003-10-30 |
| AU2003228568A1 (en) | 2003-11-03 |
| CA2482769C (en) | 2013-10-08 |
| CN1653193A (zh) | 2005-08-10 |
| DE60316547T2 (de) | 2008-07-03 |
| EP1495142A4 (de) | 2005-06-29 |
| EP1495142A1 (de) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402271A2 (hu) | Pseudoplectania nigrellá-ból származó antimikrobiális polipeptidek | |
| DK1470144T3 (da) | Oligonukleotider omfattende alternerende segmenter og anvendelser deraf | |
| ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| WO2003060084A3 (en) | Methods for making polynucleotides and purifying double-stranded polynucleotides | |
| BR0312121A (pt) | xinalases, ácidos nucléicos codificando-as e métodos para preparar e empregá-las | |
| DE60225586D1 (de) | ||
| WO2002074979A3 (en) | Expression profiles and methods of use | |
| ATE423221T1 (de) | Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung | |
| DK1178999T3 (da) | L-RIBO-LNA-analoger | |
| BRPI0315652B8 (pt) | molécula de ácido nucleico isolada, vetor, polipeptídeo de fusão, e, multímero | |
| DE60228212D1 (de) | Neue expressionsvektoren | |
| IL175021A0 (en) | Chromatin insulator, its preparation and use in protein expression | |
| TR200002989T2 (tr) | Heliomisin için gen kodu ve bunun kullanılması. | |
| HUP0101991A2 (hu) | Peszticid toxinok és az ezeket kódoló nukleotid szekvenciák | |
| DE60316547D1 (de) | Doping bei der walk-through-mutagenese | |
| ATE196926T1 (de) | Gen grb3-3, variante und ihre verwendungen | |
| WO1999014337A3 (en) | New plant genes | |
| ATE322543T1 (de) | Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz | |
| SG146640A1 (en) | Isolated photoprotein mtclytin, and use thereof | |
| ATE408621T1 (de) | Dna moleküle | |
| WO2001092468A3 (en) | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof | |
| ATE414905T1 (de) | Diabetesmodell | |
| EP1634951A4 (de) | Neues protein | |
| WO2005017112A3 (en) | Methods of inhibiting cancer growth by binding to nuclear receptors | |
| WO2002046378A3 (en) | Alternative pol k nucleotide and amino acid sequence and methods for using |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |